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MATERIALS AND METHODS
Anti-lymphocyte serum was prepared using the
technique described by Gray (14). Thyrnuses and
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inguinal lymph nodes were excised from mice and
the tissues pressed through stainless steel mesh
into Hank's balanced salt solution. The resulting
cell suspension, composed mostly of lymphoid
cells, was washed three times in normal saline,
resuspended in 5 ml saline and injected intra-
venously into the ear vein of a white rabbit
(weight about 2.5 kilograms). Between 5 X 10
and 1 X 10° cells were injected. A similar injec-
tion was given 14 days later. One week after the
second injection, the rabbit was sacrificed by ex-
posing him to a lethal dose of ether and the blood
was collected by cardiac puncture. The blood was
allowed to coagulate. The serum was removed,
heated to 56°C for one-half hour, and absorbed
with red blood cells from B-57 mice. The leuko-
cyte-agglutination titer, using cells obtained
from thymuses, was 1:512. No such agglutination
occurred with serum from untreated rabbits.
B-16 malignant melanoma was transplanted
into 75 inbred mice of the C-Si strain. These
mice were 2 weeks post-weaning. Transplanta-
tion was accomplished with minced melanoma in
Eagle's minimum essential medium. The tumor
was obtained from mice 14 days after transplan-
tation. Three small tumor fragments (rice-grain
size) were implanted subcutaneously into the
right axilla of each mouse with a 13-gauge tro-
char. The mice were divided into 2 groups. Group
I (40 mice) was studied for longevity after tumor
transplantation. Group II (35 mice, of whom 31
survived 14 days) was autopsied at 14 days and
examined for the presence of metastases. Half
the mice of each group were injected subcutane-
ously with 0.3 ml anti-lymphocyte serum on days
0, 2, 4, 6 and 8 after transplantation.
In addition, a control group of 10 mice of iden-
tical ages as Groups I and II received the same
amount of anti-lymphocyte serum but did not re-
ceive tumor transplants.
RESULTS
Group I was studied for leigth of survival
of the mice after transplantation of B-16
melanoma. Starthg at 15 days, mortality was
significantly higher ii the sub-group which re-
ceived the anti-lymphocyte serum: by 17 days
50% of the latter sub-group were dead aid
by 25 days all were dead ii this sub-group. Ii
contrast, of those mice iot receiving anti-
lymphocyte serum, 50% survived up to 23
days after traisplantatian, and 25% were still
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Primary malignant melanoma of the skii in
mai' is almost invariably associated with a
deise inflammatory infiltrate of lymphocytes
(1). Although the significance of this localized
lymphocytosis is uiknowi, oie possibility is
that these cells are immanocytes specifically
reacting agathst the tumor cells. Certain
clinico-pathological arid experimerital data can
be cited to support such a hypothesis. Thus,
(a) lymphocytes play a key role in auto
immane delayed serisitivity pheriomena (2);
(b) lymphocytes influence tumor trarisplarits
(3); (c) lymphocytes are found iri abundance
in the halo-nevus iri which nevus cells are
destroyed (4) ; arid, (d) a direct correlation
between the degree of lymphocytic infiltratiori
iri tumor tissue and patient survival has been
reported (5).
It has been showri recently that profourid
suppressiori of delayed immune phenomena
can be produced by heterologous anti-lympho-
cyte sera (6). As examples, anti-lymphocyte
serum can prolong skin allografts and xeno-
grafts (7, 8, 9); suppress allergic contact
dermatitis (10) ; diminish delayed skin reac-
tions to allergens (11) ; and delay rejection of
organ transplants (7, 12, 13).
With the above in mind the present ex-
periments were undertaken to see if anti—
lymphocyte serum directed against C-57 mouse
lymphocytes would influence the behavior of
B-16 malignant melanornas transplanted into
members of this animal species.
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TRANSPLANTATION OF MELANOMA
FIG. 1. Effect of anti-lymphocyte serum on longevity
TABLE I
Percentaqe of tumor takes (after 40 days)
Anti-lymphocyte serum and transplan- 100%
tation (20 mice)
Transplantation alone (20 mice) 85%
TABLE II
Average volume of tumor 14 days
after transplantation
Anti-lymphocyte serum and 3.12 0.15 Ml.
transplantation (17 mice)
Transplantation alone (14 2.04 0.31 Ml.
mice)
= 3.18, p = <.01.
alive at 36 days (Fig. 1). All mice receiving
only anti-lymphocyte serum were alive and
seemingly well at 36 days.
During the first 40 days after transplanta-
tion the percentage of tumor takes in Group I
was 100% in the 20 animals treated with
serum and 85% in the 20 mice receiving trans-
plantation alone (Table I).
Group II, autopsied 14 days after trans-
plantation, included 17 mice which had re-
ceived serum plus transplants, and 14 which had
received transplants alone. The average volume
of the tumors in the sub-group receiving anti-
lymphocyte serum was about 50% greater than
that in the group not receiving serum (Table
II). Furthermore, the percentage of animals
with subcutaneous and internal metastases
was greater in the group treated with anti-
lymphocyte serum (Table III). In the animals
treated with serum, metastases were found in
the parietal and visceral peritoneum in 65%,
in the liver in 29%, in the diaphragm in 35%,
and in the kidneys, ovaries and other organs
in 24%. In contrast, no animal in the group
receiving tumor transplants alone had metas-
tases to internal organs. Table IV shows that
the degree of metastases (arbitrarily indicated
as 1+ to 4+ based on the number and size
of metastatic loci) was higher in the group of
mice treated with anti-lymphocyte serum than
in the control group which did not receive the
serum.
DISCUSSION
All parameters studied (longevity, tumor
volume, incidence and degree of metastases)
show that anti-lymphocyte serum enhances the
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ANTI-LYMPHOCYTE SERUM
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TABLE III
Percentage of animals with metastases by site
Site of metastasis
Lung Mediasti-num Peritoneum Liver Diaphragm Kidney, ovary,others
Anti-lymphocyte serum and
transplantation (17 mice)
0 0 64.9% 29.4% 35.3% 23.5%
Transplantation alone (14
mice)
0 0 42.8% 0 7.1% 0
TABLE IV
Degree of metastases (number of animals)
Degree Liver
Ab-
dominal
cavity
Dia-
phragm
Anti-lymphocyte + 4 2 2
serum and trans- ++ 1 4 1
plantation (17 +++ 0 3 1
mice) ++++ 1 2 2
Transplantation + 0 2 0
alone (14 mice) ++
+++
++++
0
0
0
1
3
0
1
0
0
+, Metastases—few and/or small; ++ &
+++, Metastases—moderate in number and/or
size; ++++, Metastases—many and/or large.
growth of malignant melanoma in this experi-
mental model. Recently, Sommers and co-
workers (15) demonstrated that transplanted
human malignant melanoinas grew larger in
cortisone-conditioned hamsters which received
anti-lymphocyte serum than in similarly con-
ditioned animals which did not receive anti-
lymphocyte serum.
The most likely explanation is that lympho-
cytes have some restraining iifluence on the
growth of malignant melanomas and that this
influence is diminished or abolished by the
anti-lymphocyte serum. Although a number of
possible mechanisms for the actions of anti
lymphocyte serum has been proposed, the
most attractive explanation is that it prevents
the recognition of antigen by the lympho-
cytes (16, 17, 18).
Further studies are needed to elucidate the
component(s) present in anti—lymphocyte serum
responsible for the effects observed. Finally,
clarification is needed concerning the rela-
tionship, if any, between the increased tumor
growth and metastases reported here and
"tumor enhancement" (19). In the latter
phenomenon tumor growth is accelerated iii
animals treated with serum obtained from
tumor-bearing animals of the same species.
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